Biotechnology

A new bipartisan law injects vital funds into neuromuscular disease research, a victory driven by years of relentless patient advocacy. Here's what it means.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

A new partnership between Southern Research and Pathogenus Consulting combines US labs with a European network to fast-track treatments for global health threats.

Regulators deem PRRS-resistant pigs safe, promising a future with less animal disease and antibiotic use, but sparking debate on consumer transparency.

A bipartisan bill in Congress aims to give veterans access to emerging mental health treatments, including the novel, non-hallucinogenic compound MEAI.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

A new partnership aims to slash waste and streamline clinical trials, heralding a tech-driven transformation in the backbone of drug development.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Amid a relentless outbreak, Brazil launches a massive pilot program for the IXCHIQ® vaccine, a critical test for public health and global preparedness.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

With strong 2025 results as a tailwind, Agilent's upcoming Q1 earnings report will test its ambitious guidance and signal trends for the life sciences industry.

Bolstered by a massive capital infusion and strong investor demand, Vaxcyte is set to accelerate its broad-spectrum vaccine pipeline against market leaders.

Bermuda insurer Relm adds C-suite leaders from AXIS and Zurich, signaling a strategic push to dominate insurance for AI, crypto, and space tech.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?